TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07223229: A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo

Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 45 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,973,200

Rescue Site Savings

+$2,631,600

Unlock Full NCT07223229 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07223229 Rescue Dossier →